CIRM Funded Clinical Trials

Stem Cell Gene Therapy for HIV Mediated by Lentivector Transduced, Pre-selected CD34+ Cells in AIDS lymphoma patients


Disease Area:
HIV-related Lymphoma, HIV/AIDS
Investigator:
CIRM Grant:
CLIN2-08289 (Active)
Award Value:
$8,414,265.00
Trial Stage:
Phase 1/2
Trial Status:
Active, not recruiting
Targeted Enrollment:
11
ClinicalTrials.gov ID:

Details:

A team at UC Davis is taking a patient’s blood forming stem cells and inserting three anti-HIV genes into them and then returning them to the individual to help rebuild their immune system. The anti-HIV genes are then passed on to all new immune system cells, which makes them resistant to HIV. Because AIDS-related lymphoma is linked to the constant immune cell stimulation caused by HIV infection, getting rid of the virus should prevent return of the cancer.

Design:

Open label, single arm study.

Goal:

Safety. Efficacy - immune reconstitution, viral load and HIV status.

Contact Trial Sponsor